Our findings provide no suggestions regarding therapeutic application against HSP induced by SPAST dysfunction due to mutations in this region but might provide a new insight for HSP therapeutics by regulating the quantity of SPAST-M1 protein. This evidence concerns the gene SPAST and hereditary spastic paraplegia.